News & Insights
It’s time to bridge the gap with Avec® and experience discovery at unprecedented speeds.
As CMO, Dr. Embi works across the organization to ensure our technologies address the driving issues and challenges of both researchers and physicians.
"We’re providing physicians and researchers the ability to view, analyze and experiment with aggregated data from disparate sources on a global scale. If there’s any way that we can improve on that process, and increase our clients’ speed of discovery, we are going to do it," said CEO John Raden.
The search for true interoperability can be time consuming, frustrating, and confusing. Wide claims are often made about data integration solutions, only to later find they aren’t truly interoperable—and the chatter at HIMSS will be no different. The best way to ensure a satisfying conference experience is to pull the plug on the propaganda and get prepared.
Cut through the clutter by using the three C’s of true interoperability as your guide: care, collaboration and cost.
Avec® securely connects disparate clinical trial and health data among clinical research networks—accelerating discover
In the fourth video in our series we talk about what drives our work each day: the human impact of Avec®. In the HIT industry, it’s easy to hone in on the large amounts of disparate data in need of integration and lose sight of its origin. But at Signet Accel, true interoperability is about more than code. Every piece of data represents a friend, loved one, family member or a colleague in need of or receiving care.
By Kimberley Ferguson, Executive Vice President, Sales & Marketing
Will we be asking our doctors for Watson by name? IBM is counting on it.